Home > Journals > Chirurgia > Past Issues > Chirurgia 2022 October;35(5) > Chirurgia 2022 October;35(5):275-81

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   

Chirurgia 2022 October;35(5):275-81

DOI: 10.23736/S0394-9508.22.05495-X

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

Monoclonal antibodies and oral pills for COVID-19: new possibilities for solid organ transplanted patients?

Francesca SPIRITO 1, Vito C. CAPONIO 1, Gianluigi MAZZOCCOLI 2, Lorenzo LO MUZIO 1, 3

1 Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy; 2 IRCCS Casa Sollievo della Sofferenza Foundation, San Giovanni Rotondo, Foggia, Italy; 3 Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO), Chieti, Italy



Since January 2020, the SARS-CoV-2 pandemic remains the leading health problem worldwide. In light of the use of DNA and RNA- based vaccines as a weapon to reduce the spread of the virus, an important question is the management of immunosuppressed patients such as those solid organ transplant recipients (SOTRs), who have not been included in the phase I-III clinical trials that considered immunosuppressive or immunodeficient state among main exclusion criteria during study subjects’ enrollment. This is the reason for which there are currently no consolidated scientific data to support the safety and efficacy of nucleic acid-based vaccines in organ transplant patients. Furthermore, this population has a reduced humoral immune response to DNA and RNA vaccines compared to the immunocompetent counterpart, thus remaining at high risk for COVID-19. Another emerging problem is the reduced seroconversion to SARS-CoV-2 in transplant recipients. These patients appear to be less likely than immunocompetent patients to develop neutralizing antibodies postinfection. Therefore, the immune-compromised patients need to maintain strict precautions for COVID-19 even postvaccination, and other therapeutic and preventive tools such as monoclonal antibodies and oral antiviral pills should be considered as an additional strategy against the virus in these patients.


KEY WORDS: COVID-19; SARS-CoV-2; Vaccines; Transplant recipients; Antibodies, monoclonal

top of page